Procaps Group S.A

NASDAQ:PROC  
2.71
+0.01 (+0.37%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)305.75M
Current PE5.86
Forward PE 9.68
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$110.6 Million
Adjusted EPS$0.09
See more estimates
10-Day MA$2.70
50-Day MA$3.04
200-Day MA$3.40
See more pivots

Procaps Group S.A Stock, NASDAQ:PROC

9 rue de Bitbourg, Luxembourg, Luxembourg 1273
Luxembourg
Phone: +352.7995.6138
Number of Employees:

Description

Procaps Group SA is an international healthcare and pharmaceutical company. The firm is engaged in the developing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It operates through the following segments: NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. The NextGel segment is involved in the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in USA, Brazil, and Colombia. The Procaps Colombia segment is focused on the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Colombia. The CAN segment deals with the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Northern Central America: Salvador, Guatemala, Nicaragua, and Honduras. The CASAND segment offers pharmaceutical products in Southern Central America that include Panama and Costa Rica, and the North Andes District that include Ecuador, Peru, and Bolivia. The Diabetrics segment consists of the diabetes solutions and chronic disease management tool. The company was founded by Ruben Minski in 1977 and is headquartered in Luxembourg.